Outcomes in Hodgkin Lymphoma Patients Following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial

Amanda Cashen; Edward Agura; Jeffrey Matous; Sally Arai; Andy I. Chen; Auayporn Nadamanee; Ramón García-Sanz; Angelo Carella; Dirk Huebner; Emily K. Larsen; Juan Pinelli; Veronika Bachanova

doi:10.1016/J.BBMT.2016.12.095

Outcomes in Hodgkin Lymphoma Patients Following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial

Amanda Cashen
, Edward Agura
, Jeffrey Matous
, Sally Arai
, Andy I. Chen
, Auayporn Nadamanee
, Ramón García-Sanz
, Angelo Carella
, Dirk Huebner
, Emily K. Larsen
, Juan Pinelli
, Veronika Bachanova

Presbyterian/St. Luke's Medical Center

Washington University in St. Louis
Baylor University Medical Center
Stanford University
Oregon Health & Science University
City of Hope National Medical Center
Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
Universitaria San Martino-Ist, Genova, Italy
Takeda Pharmaceutical Company
Seattle Genetics
University of Minnesota

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Biology of Blood and Marrow Transplantation
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/J.BBMT.2016.12.095
State	Published - Mar 1 2017

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1016/J.BBMT.2016.12.095License: Unspecified

Cite this

Cashen, A., Agura, E., Matous, J., Arai, S., Chen, A. I., Nadamanee, A., García-Sanz, R., Carella, A., Huebner, D., Larsen, E. K., Pinelli, J., & Bachanova, V. (2017). Outcomes in Hodgkin Lymphoma Patients Following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial. Biology of Blood and Marrow Transplantation, 23(3). https://doi.org/10.1016/J.BBMT.2016.12.095

Outcomes in Hodgkin Lymphoma Patients Following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial. / Cashen, Amanda; Agura, Edward; Matous, Jeffrey et al.
In: Biology of Blood and Marrow Transplantation, Vol. 23, No. 3, 01.03.2017.

Research output: Contribution to journal › Article › peer-review

Cashen, A, Agura, E, Matous, J, Arai, S, Chen, AI, Nadamanee, A, García-Sanz, R, Carella, A, Huebner, D, Larsen, EK, Pinelli, J & Bachanova, V 2017, 'Outcomes in Hodgkin Lymphoma Patients Following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial', Biology of Blood and Marrow Transplantation, vol. 23, no. 3. https://doi.org/10.1016/J.BBMT.2016.12.095

@article{f070a6660bb4414d8685b83e9dc799be,

title = "Outcomes in Hodgkin Lymphoma Patients Following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial",

author = "Amanda Cashen and Edward Agura and Jeffrey Matous and Sally Arai and Chen, \{Andy I.\} and Auayporn Nadamanee and Ram{\'o}n Garc{\'i}a-Sanz and Angelo Carella and Dirk Huebner and Larsen, \{Emily K.\} and Juan Pinelli and Veronika Bachanova",

note = "Background: Allogeneic transplantation (alloHCT) has historically represented the last treatment strategy with curative potential for patients (pts) with multiple relapsed/refractory Hodgkin lymphoma (HL). However, alloHCT for HL is associated with high rates of transplant-related mortality and 3-year overall survival of approximately 30\% [1,2].",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/J.BBMT.2016.12.095",

language = "American English",

volume = "23",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1523-6536",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Outcomes in Hodgkin Lymphoma Patients Following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial

AU - Cashen, Amanda

AU - Agura, Edward

AU - Matous, Jeffrey

AU - Arai, Sally

AU - Chen, Andy I.

AU - Nadamanee, Auayporn

AU - García-Sanz, Ramón

AU - Carella, Angelo

AU - Huebner, Dirk

AU - Larsen, Emily K.

AU - Pinelli, Juan

AU - Bachanova, Veronika

N1 - Background: Allogeneic transplantation (alloHCT) has historically represented the last treatment strategy with curative potential for patients (pts) with multiple relapsed/refractory Hodgkin lymphoma (HL). However, alloHCT for HL is associated with high rates of transplant-related mortality and 3-year overall survival of approximately 30% [1,2].

PY - 2017/3/1

Y1 - 2017/3/1

UR - https://www.astctjournal.org/article/S1083-8791(16)30635-8/abstract

U2 - 10.1016/J.BBMT.2016.12.095

DO - 10.1016/J.BBMT.2016.12.095

M3 - Article

SN - 1523-6536

VL - 23

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 3

ER -

Outcomes in Hodgkin Lymphoma Patients Following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial

Disciplines

Access to Document

Other files and links

Cite this